Editas-Logo-Small (1).jpg
Editas Medicine Announces Second Quarter 2017 Results and Update
August 09, 2017 16:03 ET | Editas Medicine
Leber Congenital Amaurosis type 10 (LCA10) product candidate EDIT-101 made significant progress toward clinical trials Achieved research milestone in Juno Therapeutics, Inc., collaboration ...
Editas-Logo-Small (1).jpg
Editas Medicine to Host Conference Call Discussing Second Quarter 2017 Corporate Update and Results
August 07, 2017 08:00 ET | Editas Medicine
CAMBRIDGE, Mass., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas-Logo-Small (1).jpg
Editas Medicine to Participate in Investor Conferences in June
June 13, 2017 08:00 ET | Editas Medicine
CAMBRIDGE, Mass., June 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
Editas-Logo-Small (1).jpg
Editas Medicine Names Andrew Hirsch to Board of Directors
May 31, 2017 16:01 ET | Editas Medicine
CAMBRIDGE, Mass., May 31, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Andrew Hirsch to its board of directors,...
Editas-Logo-Small (1).jpg
Editas Medicine Announces First Quarter 2017 Results and Update
May 15, 2017 16:01 ET | Editas Medicine
Entered strategic R&D alliance with ophthalmology leader Allergan to develop and commercialize ground-breaking medicines for patients with serious eye diseases Completed successful follow-on...
Editas-Logo-Small (1).jpg
Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas
May 13, 2017 11:05 ET | Editas Medicine
CAMBRIDGE, Mass., May 13, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating the first...
Editas-Logo-Small (1).jpg
Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia
May 11, 2017 09:15 ET | Editas Medicine
CAMBRIDGE, Mass., May 11, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from its pre-clinical hematopoietic stem cell (HSC)...
Editas-Logo-Small (1).jpg
Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results
May 08, 2017 16:01 ET | Editas Medicine
CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Monday,...
Editas-Logo-Small (1).jpg
Editas Medicine to Present at Investor Conferences in May
May 08, 2017 16:01 ET | Editas Medicine
CAMBRIDGE, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that management will participate in two upcoming investor...
Editas-Logo-Small (1).jpg
Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting
April 24, 2017 14:17 ET | Editas Medicine
Oral presentation of first achievement of in vivo retinal gene editing in non-human primates Oral presentation of results demonstrating the potential of CRISPR/Cas9 gene editing to treat sickle cell...